HCL Partners with Oracle to Improve Pharmaceutical Supply Chain Integrity

HCL Partners with Oracle to Improve Pharmaceutical Supply Chain Integrity

SUNNYVALE, CA/Noida, September 20, 2010, 2010 - (Virtual Press Office) - HCL Technologies, one of the leading global IT services providers, today announced a strategic, go-to-market partnership with Oracle to help pharmaceutical organizations comply with new and increasingly stringent regulatory requirements while reducing business risk.

Driven by customer demand, HCL and Oracle have come together to offer a co-developed Oracle Pedigree and Serialization Manager Integration for Oracle's E-Business Suite, leveraging HCL's deep product and industry experience in systems integration.

As a full service provider, HCL helps organizations transform their businesses and dramatically accelerate and optimize the value of their Oracle investments over the entire business lifecycle. This partnership will help support HCL's customers in the life sciences industry to facilitate compliance with emerging electronic pedigree (ePedigree) initiatives and regulatory requirements and reduce business and reputational risk associated with the rising incidence of drug counterfeiting and product diversion.

The joint HCL and Oracle Pedigree and Serialization Manager E-Business Suite generates, stores, transmits and authenticates drug product serial data and ePedigree data as pharmaceutical products move across the supply chain. This facilitates counterfeit threat identification and streamlines compliance. Additionally, integrated analytics within the solution provide pharmaceutical manufacturers with expanded insight into possible threats.

Pharmaceutical companies can also use the E-Business Suite to improve the efficiency and accuracy of returns management and reduce associated losses. Although it is designed to address the product identification needs of pharmaceutical companies, the solution can be used in any industry dealing in high-value products at risk of counterfeiting and piracy, such as medical devices, high technology, or luxury goods.

"Ensuring supply chain integrity is not only about compliance and protecting your brand, it's also about protecting your bottom line," said Arvindh Balakrishnan, vice president, Life Sciences, Oracle. "We have chosen HCL as our strategic partner for its depth of technology and pharmaceutical domain experience across the process landscape, coupled with its flexibility to engage and a commitment to deliver. Together, we will help life sciences organizations achieve safer, more secure supply chains, combined with strong returns on investments."

"Increasingly faced with mounting pricing pressures and changing regulatory requirements, many global pharmaceutical and life sciences companies are struggling to achieve profitable growth," said Pradep Nair, vice president, Life Sciences and Health Care Practice, HCL. "We are proud that our growing leadership in pharmaceutical and healthcare has positioned HCL as a strategic partner for Oracle, and we are committed to creating transformational value for customers leveraging the Oracle Pedigree and Serialization Manager E-Business Suite to improve supply chain integrity and reduce business risk."

HCL's Life Science, Healthcare & Chemical Practice has emerged as one of the fastest growing groups amongst India IT services providers. It delivers business aligned IT services for the medical device, pharmaceuticals, chemical, and healthcare industries. With its multi-service capabilities, including domain consulting, design collaboration & manufacturing, IT services, BPO and infrastructure, HCL creates significant business value for many leading global pharmaceutical, healthcare and device OEM organizations.

About HCL Axon
HCL AXON, a division of HCL Technologies, is a leading global business transformation service firm delivering ERP solutions and services for large organizations across the world. HCL AXON has delivered numerous industry firsts in the SAP market, implementing the first Business Warehouse, Strategic Enterprise Management and eBusiness solutions. HCL AXON has offices across North America, Africa, Asia Pacific and Europe, and delivers solutions in more than 20 countries across the globe.

About HCL Technologies
HCL Technologies is a leading global IT services company, working with clients in the areas that impact and redefine the core of their businesses. Since its inception into the global landscape after its IPO in 1999, HCL focuses on ‘transformational outsourcing', underlined by innovation and value creation, and offers integrated portfolio of services including software-led IT solutions, remote infrastructure management, engineering and R&D services and BPO. HCL leverages its extensive global offshore infrastructure and network of offices in 26 countries to provide holistic, multi-service delivery in key industry verticals including Financial Services, Manufacturing, Consumer Services, Public Services and Healthcare. HCL takes pride in its philosophy of ‘Employee First' which empowers our 64,557 transformers to create a real value for the customers. HCL Technologies, along with its subsidiaries, had consolidated revenues of US$ 2.7 billion (Rs. 12,565 crores), for the year ended as on 30th June 2010. For more information, please visit http://www.hcltech.com.

About HCL Enterprise
HCL is a $5 billion leading global technology and IT enterprise comprising two companies listed in India - HCL Technologies and HCL Infosystems. Founded in 1976, HCL is one of India's original IT garage start-ups. A pioneer of modern computing, HCL is a global transformational enterprise today. Its range of offerings includes product engineering, custom & package applications, BPO, IT infrastructure services, IT hardware, systems integration, and distribution of information and communications technology (ICT) products across a wide range of focused industry verticals. The HCL team consists of over 64,000 professionals of diverse nationalities, who operate from 26 countries including over 500 points of presence in India. HCL has partnerships with several leading Global 1000 firms, including leading IT and Technology firms. For more information, please visit http://www.hcl.com.

Forward - looking Statements
Certain statements in this release are forward-looking statements, which involve a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those in such forward-looking statements. All statements, other than statements of historical fact are statements that could be deemed forward looking statements, including but not limited to the statements containing the words 'planned', 'expects', 'believes', 'strategy', 'opportunity', 'anticipates', 'hopes' or other similar words. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding impact of pending regulatory proceedings, fluctuations in earnings, our ability to manage growth, intense competition in IT services, Business Process Outsourcing and consulting services including those factors which may affect our cost advantage, wage increases in India, customer acceptances of our services, products and fee structures, our ability to attract and retain highly skilled professionals, our ability to integrate acquired assets in a cost effective and timely manner, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, the success of our brand development efforts, liability for damages on our service contracts, the success of the companies / entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property, other risks, uncertainties and general economic conditions affecting our industry. There can be no assurance that the forward looking statements made herein will prove to be accurate, and issuance of such forward looking statements should not be regarded as a representation by the Company, or any other person, that the objective and plans of the Company will be achieved. All forward looking statements made herein are based on information presently available to the management of the Company and the Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.

For details contact

Kirsten Paragona
Director of External Communications, HCL
857-350-5393
[email protected]

Danielle Millerick
BluePoint Marketing for HCL
781-861-7800
[email protected]

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.